Measuring the response of human head and neck squamous cell carcinoma to irradiation in a microfluidic model allowing customized therapy
Authors:
Open Access
- 5 September 2017
- journal article
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 51 (4) , 1227-1238
Abstract
Radiotherapy is the standard treatment for head and neck squamous cell carcinoma (HNSCC), however, radioresistance remains a major clinical problem despite significant improvements in treatment protocols. Therapeutic outcome could potentially be improved if a patient's tumour response to irradiation could be predicted ex vivo before clinical application. The present study employed a bespoke microfluidic device to maintain HNSCC tissue whilst subjecting it to external beam irradiation and measured the responses using a panel of cell death and proliferation markers. HNSCC biopsies from five newly-presenting patients [2 lymph node (LN); 3 primary tumour (PT)] were divided into parallel microfluidic devices and replicates of each tumour were subjected to single-dose irradiation (0, 5, 10, 15 and 20 Gy). Lactate dehydrogenase (LDH) release was measured and tissue sections were stained for cytokeratin (CK), cleaved-CK18 (cCK18), phosphorylated-H2AX (γH2AX) and Ki‑67 by immunohistochemistry. In addition, fragmented DNA was detected using terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL). Compared with non‑irradiated controls, higher irradiation doses resulted in elevated CK18-labelling index in two lymph nodes [15 Gy; 34.8% on LN1 and 31.7% on LN2 (p=0.006)] and a single laryngeal primary tumour (20 Gy; 31.5%; p=0.014). Significantly higher levels of DNA fragmentation were also detected in both lymph node samples and one primary tumour but at varying doses of irradiation, i.e., LN1 (20 Gy; 27.6%; p=0.047), LN2 (15 Gy; 15.3%; p=0.038) and PT3 (10 Gy; 35.2%; p=0.01). The γH2AX expression was raised but not significantly in the majority of samples. The percentage of Ki‑67 positive nuclei reduced dose-dependently following irradiation. In contrast no significant difference in LDH release was observed between irradiated groups and controls. There is clear inter- and intra-patient variability in response to irradiation when measuring a variety of parameters, which offers the potential for the approach to provide clinically valuable information.Keywords
This publication has 50 references indexed in Scilit:
- Immunotherapy and Checkpoint Inhibitors in Recurrent and Metastatic Head and Neck CancerAmerican Society of Clinical Oncology Educational Book, 2016
- Radiosensibilité et/ou résistance des cancers ORL : aspects biologiquesBulletin du Cancer, 2016
- Head and neck cancer: causes, prevention and treatmentBrazilian Journal of Otorhinolaryngology, 2015
- Paramètres de radiorésistance des cancers des voies aérodigestives supérieures et stratégies de radiosensibilisationCancer/Radiothérapie, 2015
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Differential proteomics in the search for biomarkers of radiotherapy resistanceExpert Review of Proteomics, 2011
- DNA Repair Biomarker Profiling of Head and Neck Cancer: Ku80 Expression Predicts Locoregional Failure and Death following RadiotherapyClinical Cancer Research, 2011
- Squamous cell carcinoma of the head and neck: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2010
- EGFR, p16, HPV Titer, Bcl-xL and p53, Sex, and Smoking As Indicators of Response to Therapy and Survival in Oropharyngeal CancerJournal of Clinical Oncology, 2008
- Molecular biomarkers and site of first recurrence after radiotherapy for head and neck cancerEuropean Journal of Cancer, 2004